TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,027,000 | +41.8% | 166,201 | +50.8% | 0.23% | +154.3% |
| Q1 2022 | $2,840,000 | -16.8% | 110,225 | +0.3% | 0.09% | -25.8% |
| Q4 2021 | $3,412,000 | +161.7% | 109,925 | +104.4% | 0.12% | +210.0% |
| Q3 2021 | $1,304,000 | -15.2% | 53,790 | -49.0% | 0.04% | -16.7% |
| Q2 2021 | $1,538,000 | -51.3% | 105,382 | -16.7% | 0.05% | -46.7% |
| Q1 2021 | $3,160,000 | – | 126,533 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |